USE OF HIVID WITH DRUGS THAT HAVE THE POTENTIAL TO CAUSE PERIPHERAL NEUROPATHY SHOULD BE AVOIDED WHERE POSSIBLE, LIKE ANTIRETROVIRAL NUCLEOSIDE ANALOGUES, CHLORAMPHENICOL, AMPHOTERICIN, FOSCARNET, AMINOGLYCOSIDES, CISPLATIN, DAPSONE, DISULFIRAM, ETHIONAMIDE, GLUTETHIMIDE, GOLD, HYDRALAZINE, IODOQUINOL, ISONIAZID, METRONIDAZOLE, NITROFURANTOIN, PHENYTOIN, RIBAVIRIN, AND VINCRISTINE.
CONCOMITANT USE OF HIVID WITH DIDANOSINE IS NOT RECOMMENDED.
CONCOMITANT USE OF ZALCITABINE AND LAMIVUDINE IS NOT RECOMMENDED.
TREATMENT WITH ZALCITABINE SHOULD BE INTERRUPTED WHEN THE USE OF A DRUG THAT HAS THE POTENTIAL TO CAUSE PANCREATITIS IS REQUIRED LIKE PENTAMIDINE.
CONCOMITANT ADMINISTRATION OF PROBENECID OR CIMETIDINE DECREASES THE ELIMINATION OF ZALCITABINE. ABSORPTION OF ZALCITABINE IS MODERATELY REDUCED (APPROXIMATELY 25%) WHEN COADMINISTERED WITH MAGNESIUM/ALUMINUM-CONTAINING ANTACID PRODUCTS. BIOAVAILABILITY IS MILDLY REDUCED (APPROXIMATELY 10%) WHEN ZALCITABINE AND METOCLOPRAMIDE ARE COADMINISTERED. DOXORUBICIN CAUSED A DECREASE IN ZALCITABINE PHOSPHORYLATION ( > 50% INHIBITION OF TOTAL PHOSPHATE FORMATION)